Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Arch Dermatol ; 148(9): 1047-52, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22986858

RESUMO

BACKGROUND: Central centrifugal cicatricial alopecia is the most common form of cicatricial alopecia in African American women. Treatment options are limited and mostly aimed at halting further hair loss but rarely result in hair regrowth. Therefore, it is important to recognize early clinical signs, perform a confirmatory biopsy, and begin treatment promptly. We have observed that hair breakage may be a key sign of early central centrifugal cicatricial alopecia, and this association is not clearly described in the literature. OBSERVATIONS: Nine patients with hair breakage on the vertex with or without scalp symptoms underwent scalp biopsies as part of their evaluation. Of these, 8 had histologic samples adequate for complete interpretation: 5 specimens (63%) showed histologic changes typical of central centrifugal cicatricial alopecia, with 1 of these showing advanced end-stage changes of cicatricial alopecia. Two (25%) revealed premature desquamation of the inner root sheath as the sole finding suggestive of early central centrifugal cicatricial alopecia and 1 (13%) was normal. CONCLUSIONS: Although hair breakage can have multiple causes, early central centrifugal cicatricial alopecia must be considered in the differential diagnosis, particularly in women of African ancestry. Histologic evaluation may reveal early or late findings that can help establish the diagnosis.


Assuntos
Alopecia/diagnóstico , Cabelo , Adulto , Negro ou Afro-Americano , Alopecia/complicações , Progressão da Doença , Diagnóstico Precoce , Feminino , Cabelo/patologia , Humanos , Pessoa de Meia-Idade , Estudos Retrospectivos
2.
J Clin Aesthet Dermatol ; 5(6): 37-40, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22768355

RESUMO

Central centrifugal cicatricial alopecia is a scarring alopecia that is predominantly seen in African American women, but occurs less frequently in men. The authors present three cases of African American men with biopsy-proven central centrifugal cicatricial alopecia and detail the clinical presentation, histological findings, and treatment regimens. Central centrifugal cicatricial alopecia should be considered in the differential diagnosis when evaluating male patients with vertex hair loss accompanied by scalp symptoms. Physicians should maintain a high index of suspicion in African American men with the appropriate clinical picture and confirm the diagnosis by scalp biopsy. Prompt and appropriate treatment can help halt or slow disease progression.

3.
Dermatol Surg ; 37(7): 901-17, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21585594

RESUMO

BACKGROUND: Dark-skinned patients manifest the signs of skin aging differently than their fair-skinned counterparts in that the former exhibit more intrinsic facial aging, whereas the later shows more photodamage. Nevertheless, common cosmetic procedures can be used in skin of color to treat the signs of aging. OBJECTIVE: To provide updated clinical information on the use of cosmetic procedures for skin aging in darker phototypes for the safe treatment of this population. METHODS: A Medline literature search was performed for publications on the safety and efficacy of botulinum toxin, dermal fillers, chemical peels, laser and light-based devices, and microdermabrasion for the treatment of skin aging specifically in ethnic populations. RESULTS: Similarly to light-skinned patients, botulinum toxin and dermal fillers provide fast, effective results in skin of color, with fewer complications than with traditional surgery and no downtime. More-invasive procedures, such as chemical peeling, laser resurfacing, and microdermabrasion, can also be effective, but it is important to exercise caution and remain within certain parameters given the greater risk of dyschromias in this population. CONCLUSION: With the proper knowledge of how to treat aging skin of color, these patients can experience the benefits of cosmetic procedures while minimizing the risks.


Assuntos
Técnicas Cosméticas , Procedimentos Cirúrgicos Dermatológicos , Grupos Raciais , Envelhecimento da Pele/etnologia , Toxinas Botulínicas Tipo A/efeitos adversos , Toxinas Botulínicas Tipo A/uso terapêutico , Abrasão Química/efeitos adversos , Cicatriz/etiologia , Colágeno/efeitos adversos , Colágeno/uso terapêutico , Dermabrasão/efeitos adversos , Humanos , Terapia a Laser/efeitos adversos , Viscossuplementos/efeitos adversos , Viscossuplementos/uso terapêutico
5.
Am J Clin Dermatol ; 12(2): 87-99, 2011 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-21348540

RESUMO

Postinflammatory hyperpigmentation (PIH) is a reactive hypermelanosis and sequela of a variety of inflammatory skin conditions. PIH can have a negative impact on a patient's quality of life, particularly for darker-skinned patients. Studies show that dyschromias, including PIH, are one of the most common presenting complaints of darker-skinned racial ethnic groups when visiting a dermatologist. This is likely due to an increased production or deposition of melanin into the epidermis or dermis by labile melanocytes. A variety of endogenous or exogenous inflammatory conditions can culminate in PIH and typically most epidermal lesions will appear tan, brown, or dark brown while dermal hypermelanosis has a blue-gray discoloration. Depigmenting agents target different steps in the production of melanin, most commonly inhibiting tyrosinase. These agents include hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice (glycyrrhiza) extracts. Other agents include retinoids, mequinol, ascorbic acid (vitamin C), niacinamide, N-acetyl glucosamine, and soy, and these products depigment by different mechanisms. Certain procedures can also be effective in the treatment of PIH including chemical peeling and laser therapy. It is important to note that these same therapeutic modalities may also play a role in causing PIH. Lastly, those lesions that are not amenable to medical or surgical therapy may experience some improvement with cosmetic camouflage.


Assuntos
Hiperpigmentação/terapia , Dermatopatias/complicações , Pigmentação da Pele/efeitos dos fármacos , Abrasão Química/métodos , Cosméticos , Fármacos Dermatológicos/uso terapêutico , Humanos , Hiperpigmentação/diagnóstico , Hiperpigmentação/etiologia , Inflamação/complicações , Inflamação/fisiopatologia , Terapia a Laser/métodos , Grupos Raciais , Dermatopatias/fisiopatologia
6.
J Clin Aesthet Dermatol ; 3(4): 24-38, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20725545

RESUMO

Acne vulgaris is one of the most common conditions for which all patients, including those with skin of color (Fitzpatrick skin types IV-VI), seek dermatological care. The multifactorial pathogenesis of acne appears to be the same in ethnic patients as in Caucasians. However, there is controversy over whether certain skin biology characteristics, such as sebum production, differ in ethnic patients. Clinically, acne lesions can appear the same as those seen in Caucasians; however, histologically, all types of acne lesions in African Americans can be associated with intense inflammation including comedones, which can also have some degree of inflammation. It is the sequelae of the disease that are the distinguishing characteristics of acne in skin of color, namely postinflammatory hyperpigmentation and keloidal or hypertrophic scarring. Although the medical and surgical treatment options are the same, it is these features that should be kept in mind when designing a treatment regimen for acne in skin of color.

7.
J Clin Aesthet Dermatol ; 3(7): 20-31, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20725554

RESUMO

Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.

8.
Head Neck ; 31(1): 28-36, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18767171

RESUMO

BACKGROUND: Our aim was to review our experience with liposarcoma of the head and neck region. METHODS: This is a retrospective case series at a comprehensive cancer center (1945-2005). RESULTS: Of 30 patients, 10 (33%) were initially misdiagnosed. Local recurrences were common (overall rate = 53%), and 4 patients (13%) developed distant metastases. Decreased crude disease-specific survival rates were significantly associated with recurrence (especially distant recurrence [0%]), age less than 38 years (40%), and pleomorphic subtype (45%); however, in Kaplan-Meier analyses, only larger tumor size, negative margins, round cell subtype, and pleomorphic subtype were associated with significantly decreased disease-specific survival (log-rank test p = .048, .041, .021, and .012, respectively). CONCLUSIONS: Based on this limited experience and existing literature, we continue to recommend surgery with negative margins as the treatment of choice and that adjuvant therapies should be considered in patients with high-grade histology, large tumors, positive margins, or certain subsites.


Assuntos
Neoplasias de Cabeça e Pescoço/mortalidade , Neoplasias de Cabeça e Pescoço/cirurgia , Lipossarcoma/mortalidade , Lipossarcoma/cirurgia , Adulto , Institutos de Câncer , Terapia Combinada , Feminino , Neoplasias de Cabeça e Pescoço/tratamento farmacológico , Neoplasias de Cabeça e Pescoço/patologia , Neoplasias de Cabeça e Pescoço/radioterapia , Humanos , Estimativa de Kaplan-Meier , Lipossarcoma/tratamento farmacológico , Lipossarcoma/patologia , Lipossarcoma/radioterapia , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica , Recidiva Local de Neoplasia/epidemiologia , Prognóstico , Estudos Retrospectivos , Texas , Adulto Jovem
9.
Mol Genet Metab ; 78(1): 11-6, 2003 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-12559843

RESUMO

Argininosuccinate lyase (AL) has several roles in intermediary metabolism. It is an essential component of the urea cycle, providing a pathway for the disposal of excess nitrogen in mammals. AL links the urea cycle to the tricarboxylic acid (TCA) cycle by generating fumarate. Finally, AL is required for the endogenous production of arginine. In this latter role it may function outside ureagenic organs to provide arginine as a substrate for nitric oxide synthases (NOS). Increasing evidence suggests that argininosuccinate synthetase (AS) and AL are more globally expressed, and the coordinate regulation of AS and AL gene expression with that of the inducible form of NOS (iNOS) provides evidence that this may facilitate the regulation of NOS activity. Deficiency of AL leads to the human urea cycle disorder argininosuccinic aciduria. We produced an AL deficient mouse by gene targeting in order to investigate the role of AL in endogenous arginine production. This mouse also provides a model of the human disorder to explore the pathogenesis of the disorder and possible new treatments. Metabolic studies of these mice demonstrated that they have the same biochemical phenotype as humans, with hyperammonemia, elevated plasma argininosuccinic acid and low plasma arginine. Plasma nitrites, derived from NO, were not reduced in AL deficient mice and there was no significant difference is the level of cyclic GMP, the second messenger induced by NO.


Assuntos
Erros Inatos do Metabolismo dos Aminoácidos/enzimologia , Argininossuccinato Liase/genética , Ácido Argininossuccínico/urina , Erros Inatos do Metabolismo dos Aminoácidos/genética , Erros Inatos do Metabolismo dos Aminoácidos/urina , Animais , Arginase/metabolismo , Arginina/sangue , Argininossuccinato Liase/metabolismo , Ácido Argininossuccínico/sangue , Acidúria Argininossuccínica , Carbamoil-Fosfato Sintase (Amônia)/metabolismo , GMP Cíclico/urina , Modelos Animais de Doenças , Feminino , Genótipo , Humanos , Hiperamonemia/sangue , Masculino , Camundongos , Camundongos Endogâmicos , Camundongos Knockout , Óxido Nítrico/metabolismo , Ornitina Carbamoiltransferase/metabolismo , Ureia/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...